Almirall to commercialise Basilea's oral eczema treatment
This article was originally published in Scrip
Executive Summary
Almirall is to distribute exclusively Basilea Pharmaceutica's Toctino (alitretinoin), a once-daily oral treatment for adults with severe chronic hand eczema (CHE) unresponsive to topical corticosteroids, in Austria, Belgium, Czech Republic, Italy, Luxembourg, Mexico, the Netherlands, Poland, Portugal, Slovakia and Spain.